Total: $606.276M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@


Adventrx Pharmaceuticals Inc. (OTCBB:AVRX)

Private placement of common stock and warrants

2.5S and W

$2.5

Adventrx raised about $2.5M through a private placement with institutional and accredited investors (9/16)

Aerogen Inc. (AEGN)

Convertible debt financing

N/A

$1.45

Aerogen raised $1.45M from a two-round convert- ible debt financing from SF Capital Partners Ltd.; with a second closing scheduled for November, the company could raise a total of $2M in the financing (9/12)

Alexion Pharmaceuticals Inc. (ALXN)

Private placement of common stock

3.6S

$44

Alexion raised $44M with the sale of 3.6M shares at $13 each to a syndicate led by Bear, Stearns & Co. Inc. (9/12)

Alfacell Corp. (OTC BB:ACEL)

Private placement of common stock

1.7S and W for 0.852S

$1.5

Company completed a private placement including common stock and common stock purchase warrants to an institutional investor (9/8)

Alkermes Inc. (ALKS)

Private placement of convertible subordinated notes

N/A

$25

Alkermes raised an additional $25M in a private placement option; as a result of the overallotment the company raised $100M in August (9/9)

AMDL Inc. (AMEX:ADL)

Private placement of common stock and the exercise of warrants

1.2S and W for 1.5S

$1.369

AMDL raised $770,000 through the issuance of 1.2M shares, and another $599,247 through the exercise of warrants for 1.5M shares (9/15)

Antigenics Inc. (AGEN)

Private placement of preferred stock

N/A

$31.6

Antigenics raised $31.6M through the sale of Series A convertible preferred stock to an existing shareholder (9/19)

Aphton Corp. (APHT)

Private placement of common stock and warrants

3.9S and W for 0.98S

$22.7

Aphton raised $22.7M in the financing with institutional investors (9/17)

Axonyx Inc. (AXYX)

Private placement of common stock and warrants

7.47S and W for 5.6S

$25

Axonyx raised $25M in the private placement; Rodman & Renshaw Inc. and Punk Ziegel & Co. served as placement agents (9/12)

Biomira Inc. (Canada; BIOM)

Private placement of stock and warrants

9S and 2.1W

US$16.3

Biomira raised US$16.3M in the private placement (9/22)

BioSyntech Inc. (Canada; OTC BB:BSYI)

Private placement of units

0.000633U

C$0.633 (US$0.457)

BioSyntech raised US$457,000 after issuing 633 units at C$1,000 apiece; each unit includes 3,000 shares of common stock and warrants to acquire an additional 3,000 common shares (9/2)

Cel-Sci Corp. (AMEX:CVM)

Equity line of credit financing

N/A

--

Cel-Sci has the right to obtain as much as $10M through the issuance of common stock to its largest institutional investor (9/18)

CytRx Corp. (CYTR)

Private placement of common stock and warrants

4.1S and W for 1S

$8.7

CytRx raised $8.7M selling 4.1M shares of common stock to selected institutional investors, and issued warrants for about another 1M shares; Cappello Capital Corp. served as lead placement agent (9/17)

Epimmune Inc. (EPMN)

Private placement of common stock and warrants

2.2S and W for 0.542S

$4

Epimmune raised $4M in the private placement (9/19)

Forbes Medi-Tech Inc. (Canada; FMTI)

Private placement of common stock and warrants

3.13S and 1.16W

US$4.65

Forbes raised US$4.65M in a private placement issuing about 3.13M common shares with about 1.16M warrants attached (9/5)

Hybridon Inc. (OTC BB:HYBN)

Private placement of common stock and warrants

20S and W for 6S

$14.6

Hybridon raised $14.6M in a private financing (9/2)

Incara Pharmaceuticals Corp. (OTC BB:INCR)

Debenture and warrant purchase agreement

N/A

$5

Incara raised $5M in the financing with Goodnow Capital LLC (9/17)

InSite Vision Inc. (AMEX:ISV)

Assumption of redeemable debentures

N/A

$0.5

InSite raised $500,000 in a potential $1M interim financing from a private investment fund; J.P. Turner & Co. LLC served as financial representative (9/23)

Ligand Pharmaceuticals Inc. (LGND)

Private placement of common stock

3.48S

$47

Ligand raised $47M through the private placement with selected institutional and accredited investors (9/12)

Lynx Therapeutics Inc. (LYNX)

Private placement of common stock and warrants

0.744S and W for 0.186S

$3

Lynx completed a $3M financing with independent institutional investors (9/25)

MacroChem Corp. (MCHM)

Private placement of common stock and warrants

4.6S and W for 0.9S

$3.25

MacroChem raised $3.25M in the private placement with institutional investors; J.P. Carey Securities Inc. served as placement agent (9/12)

Maxim Pharmaceuticals Inc. (MAXM)

Private placement of common stock and warrants

4.6S and W for 1.4S

$25.5

Maxim raised $25.5M in the placement; Merriman Curhan Ford & Co. acted as the transaction's sole placement agent (9/23)

Miravant Medical Technologies Inc. (OTC BB: MRVT)

Convertible debt and warrant purchase agreement

N/A

$6

Miravent raised $6M through the agreement with a group of institutional investors, including SDS Merchant Fund LP, Versant Capital Management LLC, Symmetry Capital Management LLC and others (9/2)

Nanogen Inc. (NGEN)

Private placement of common stock and warrants

2.1S and W for 2.05S

$16

Nanogen raised $16M in the placement of 2.1M shares, as well as five-year warrants to purchase 424,243 additional common shares, one-year warrants to purchase 530,305 and six-month warrants to purchase about 1.1M common shares; Seven Hills Partners LLC acted as the financing's exclusive placement agent (9/18)

Nastech Pharmaceutical Co. (NSTK)

Private placement of common stock and warrants

1.513S and W for 0.53S

$11

Nastech raised $11M by issuing 1.513M shares of common stock and warrants to purchase up to 530,000 shares (9/5)

Neose Technologies Inc. (NTEC)

Private placement of common stock

2.7S

$23.9

Neose raised about $23.9M in the placement; JP Morgan Securities Inc. acted as placement agent (9/22)

OSI Pharmaceuticals Inc. (OSIP)

Private placement of convertible notes

N/A

$135

OSI raised $135M in a private placement (9/3)

Oxford BioMedica plc (UK; LSE:OXB)

Private placement of common stock

130S

£22.1 (US$35.3)

Oxford BioMedica raised US$35.3M in the private financing (9/17**)

Pharmos Corp. (PARS)

Convertible debt financing

N/A

$21

Pharmos raised $21M in the financing with six institutional investors (9/30)

Point Therapeutics Inc. (OTC BB:POTP)

Private placement of common stock and warrants

5.6S and W for 2.8S

$11.2

Point Therapeutics raised $11.2M; investors were ProQuest Investments, as well as certain other new and existing investors (9/22)

Prana Biotechnology Ltd. (Australia; PRAN)

Private placement of common stock

7.15S

A$5 (US$3.2)

Prana raised US$3.2M through a private placement of 7.15M shares (9/4)

Progen Industries Ltd. (Australia; PGLAF; ASX:PGL)

Private placement of common stock

6S

A$9.6 (US$6.4)

Progen raised US$6.4M through a private placement of 6M common shares to Australian investors; Taylor Collison Ltd. acted as the deal's lead broker with support from Emerging Growth Capital Pty. Ltd. (9/18)

Protalex Inc. (OTC BB:PRTX)

Private placement of common stock and warrants

7.5S and W for 2.6S

$12.7

Protalex raised about $12.7M through the private placement led by vSpring Capital; other investors were Integral Capital Partners, as well as institutional and accredited private investors including current shareholders (9/19)

Spectrum Pharmaceuticals Inc. (SPPI)

Private placement of convertible preferred stock and warrants

N/A

$20

Spectrum raised $20M in the private placement; investors were Baystar Capital, SDS Merchant Fund, SCO Capital Partners, Xmark Funds, Quogue Capital and ProMed Partners LP; SCO Securities LLC acted as placement agent (9/29)

The Immune Response Corp. (IMNR)

Exercise of warrants

2.4W

$3.2

The Immune Response Corp. raised $3.2M through the exercise of about 2.4M Class A warrants in connection with the redemption of warrants (9/10)

Vion Pharmaceuticals Inc. (VION)

Private placement of common stock and warrants

6.5S

$11.3

Vion raised $11.3M in a private placement of 6.5M shares and warrants to purchase the same amount of shares to an institutional investor (9/10)

Viventia Biotech Inc. (Canada; TSE:VBI)

Private placement of common stock

14U

C$2.8 (US$2)

Viventia raised US$2M in a private placement with Teva Pharmaceutical Industries Ltd.; each unit is one common share and one common share purchase warrant (9/5)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

** Denotes the date the item ran in BioWorld International.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments